Trump Administration Adds 9 Drugmakers to Medicaid Discount Deals, Reaching 26 Firms Covering 90% of Market
Updated
Updated · CBS New York · Aug 31
Trump Administration Adds 9 Drugmakers to Medicaid Discount Deals, Reaching 26 Firms Covering 90% of Market
3 articles · Updated · CBS New York · Aug 31
Summary
Nine additional pharmaceutical companies signed agreements to offer discounted drugs to every U.S. state Medicaid program, expanding the administration’s most-favored-nation pricing push.
Trump said the new deals bring participation to 26 companies covering 90% of the domestic pharmaceutical market, with projected savings of more than $600 billion over a short period.
The nine midsize firms are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB.
The White House said the companies also committed $19.6 billion in manufacturing spending, while the broader policy seeks to align U.S. drug prices with lower prices in other developed nations.
The agreements build on 17 earlier voluntary price-cut deals and complement TrumpRx, the administration’s February-launched website for direct consumer discounts on name-brand medicines.